Skip to main content
Clinical Trials/NCT01909193
NCT01909193
Completed
N/A

Cognitive Behavior Therapy vs. Attention Bias Modification Treatment for Social Anxiety

Hebrew University of Jerusalem1 site in 1 country69 target enrollmentJanuary 2011
ConditionsSocial Phobia

Overview

Phase
N/A
Intervention
Not specified
Conditions
Social Phobia
Sponsor
Hebrew University of Jerusalem
Enrollment
69
Locations
1
Primary Endpoint
Liebovitz Social Anxiety Scale (LSAS) - diagnostic interview
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Adults with Social Anxiety Disorder will be pseudo randomly assigned to either an individual cognitive behavior therapy, attention bias modification treatment (allocation ratio - 1.5:1).

Outcome measures will be social anxiety symptoms and severity as measured by gold standard questionnaires as well as diagnosis of social anxiety disorder derived from structured clinical interviews based on Diagnostic and Statistical Manual (DSM) IV criteria.

The investigators expect to find significant reduction in social anxiety symptoms in all of the groups, with the cognitive behavior therapy group showing greater reduction in symptoms than the other groups. Mechanisms of change in all of the groups will be examined via measures of cognitive biases, affect, and other common and specific factors.

Detailed Description

120 Adults with Social Anxiety Disorder will be pseudo randomly assigned to either an individual cognitive behavior therapy (CBT), attention bias modification treatment (ABM)). Outcome measures will be social anxiety symptoms and severity as measured by gold standard questionnaires as well as diagnosis of social anxiety disorder derived from structured clinical interviews based on DSM-IV criteria. The investigators expect to find significant reduction in social anxiety symptoms in all of the groups, with the cognitive behavior therapy group showing greater reduction in symptoms than the other groups. Mechanisms of change in all of the groups will be examined via measures of cognitive biases, affect, and other common and specific factors.

Registry
clinicaltrials.gov
Start Date
January 2011
End Date
November 2014
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jonathan D. Huppert

Associate Professor, Department of Psychology

Hebrew University of Jerusalem

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of Generalized Social Anxiety Disorder, LSAS\>50
  • If on medication, patients must be on a stable dose
  • Hebrew language fluency

Exclusion Criteria

  • Primary Axis I or Axis II disorder other than SAD
  • suicidal ideation
  • Substance dependence within the past three months or current substance abuse
  • Mental retardation or another pervasive developmental disability
  • Current or past schizophrenia or psychosis, current bipolar disorder, or organic brain syndrome

Outcomes

Primary Outcomes

Liebovitz Social Anxiety Scale (LSAS) - diagnostic interview

Time Frame: Expected time frame of up to 32 weeks per participant. Participants will be assessed before and after the administration of the treatment, every 4 weeks during treatment and at 3 months follow-up

LSAS is a 24-items clinician-administered scale developed for the assessment of fear and avoidance associated with social situations. The LSAS assesses a wide range of both social interaction and performance/observation situations, which are rated for degree of fear/anxiety and frequency of avoidance.

Secondary Outcomes

  • Social Phobia Inventory (SPIN) - self-report questionnaire(Up to 32 weeks per participant. The SPIN will be administered before and after each treatment session and at 3 months follow-up)

Study Sites (1)

Loading locations...

Similar Trials